Mellitus is dedicated to advancing diabetes detection and monitoring through products based on GCD59, a biomarker of glycemic load that is unique because of its direct relationship to the complications of diabetes. Our premier application is a patient-friendly test for gestational diabetes, enabling more timely intervention to improve the health of both mother and child. We plan to commercialize our products through strategic partners as we expand indications to benefit all individuals with diabetes. GDM also known as diabetes in pregnancy, is a major cause of adverse pregnancy outcomes for both babies and mothers. Approximately four million pregnant women are screened for GDM each year in the United States alone. Because treatment of GDM mitigates the risk of complications, practice guidelines from professional organizations such as the American College of Obstetrics and Gynecology and the American Diabetes Association recommend screening of all non-diabetic pregnant women for GDM. Current standard-of-care tests for the screening and diagnosis of GDM are time consuming, uncomfortable for the patients and are reported to have poor reproducibility, highlighting the need for an accurate, simpler and more patient-friendly test for GDM.